GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IMGT Corp Ltd (XKRX:456570) » Definitions » Construction In Progress

IMGT (XKRX:456570) Construction In Progress : ₩518.28 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is IMGT Construction In Progress?

IMGT's quarterly construction in progress declined from Dec. 2021 (₩431.60 Mil) to Dec. 2022 (₩201.07 Mil) but then increased from Dec. 2022 (₩201.07 Mil) to Dec. 2023 (₩518.28 Mil).

IMGT's annual construction in progress declined from Dec. 2021 (₩431.60 Mil) to Dec. 2022 (₩201.07 Mil) but then increased from Dec. 2022 (₩201.07 Mil) to Dec. 2023 (₩518.28 Mil).


IMGT Construction In Progress Historical Data

The historical data trend for IMGT's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMGT Construction In Progress Chart

IMGT Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Construction In Progress
- 431.60 201.07 518.28

IMGT Semi-Annual Data
Dec20 Dec21 Dec22 Dec23
Construction In Progress - 431.60 201.07 518.28

IMGT Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


IMGT (XKRX:456570) Business Description

Traded in Other Exchanges
N/A
Address
172 Dolma-ro,, 408, Healthcare Innovation Park, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13605
IMGT Corp Ltd develops a focused ultrasound-based drug delivery platform for intractable diseases. It is developing nanomedicines and focused ultrasound medical devices that respond to focused ultrasound. The firm has two pipeline products IMD20 and IMP101. IMD20 is a FUS device developed for chronic pain as a product with reduced size and output from IMD10 developed for cancer treatment. IMP101 is a nanoparticle used for hepatocarcinoma embolization.

IMGT (XKRX:456570) Headlines

No Headlines